Research
Hormonal
Semaglutide (2.4 mg) and Tirzepatide (15 mg) produce significantly greater weight loss (14.9% and 20.9% respectively) in non-diabetic obesity compared to current approved drugs, though they are associated with frequent gastrointestinal adverse events.
If you have obesity without diabetes, newer injectable medications like semaglutide or tirzepatide are currently the most effective pharmacological options, capable of reducing body weight by 15-21%. However, you must be prepared for gastrointestinal side effects like nausea and diarrhea, which are common but often manageable with gradual dose increases.
StrongSupportsHIGH confidence
Semaglutide and tirzepatide reduced the body weight of people with obesity without diabetes by 14.9% and 20.9%, respectively. However, because of the mechanism of GLP-1 receptor agonism, gastrointestinal adverse events, including nausea, diarrhea, vomiting, and abdominal pain, were problematic in many patients, although these adverse events were generally acceptable.
Why this rating
Based on large-scale Phase 3 clinical trials (STEP1, SURMOUNT-1) cited in the paper.
Source
Pharmacotherapy in obesity: the current state and the near future
Yoon Jeong Cho et al. · Journal of Korean Medical Association · 2022
narrative_reviewCited 3×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →